Coherus Oncology, Inc. Common Stock (CHRS) Stock Price

CHRSStock

$1.41+19.49%52W

Market Cap$217.85M

P/E1.05x

PEG Ratio—

Div yield—

Beta0.97

CHRS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-27.50%

Price vs S&P 500 (4W)-3.62%

VGM Score56.46

P/E Ratio (Annual)1.05x

Book Value / Share (Quarterly)$0.39

P/TBV (Annual)11.62x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-41.53%

Cash Flow / Share (Quarterly)$-1.20

Price vs S&P 500 (YTD)-13.53%

Gross Margin (TTM)68.94%

Net Profit Margin (TTM)-259.41%

EPS (TTM)$-1.03

10-Day Avg Trading Volume1.47M

EPS Excl Extra (TTM)$-1.03

Revenue Growth (5Y)-38.41%

EPS (Annual)$1.43

ROI (Annual)149.90%

Gross Margin (Annual)67.24%

Net Profit Margin (5Y Avg)18.09%

Cash / Share (Quarterly)$0.68

P/E Basic Excl Extra (TTM)1.05x

Revenue Growth QoQ (YoY)39.53%

EPS Growth (5Y)-1.96%

P/E Normalized (Annual)1.05x

ROA (Last FY)65.04%

Revenue Growth TTM (YoY)-64.32%

EBITD / Share (TTM)$-1.18

ROE (5Y Avg)-127.02%

Operating Margin (TTM)-311.56%

Cash Flow / Share (Annual)$-1.14

P/B Ratio2.90x

P/B Ratio (Quarterly)3.55x

Net Income / Employee (Annual)$1,143,000

EV / Revenue (TTM)2.85x

Net Interest Coverage (TTM)-33.01x

ROA (TTM)-42.90%

EV / EBITDA (TTM)2.52x

EPS Incl Extra (Annual)$1.43

Current Ratio (Annual)1.47x

Quick Ratio (Quarterly)1.58x

3-Month Avg Trading Volume1.08M

52-Week Price Return19.49%

P/E Incl Extra (TTM)1.05x

Revenue / Employee (TTM)$346,500

Tangible BV / Share (Quarterly)$0.10

P/S Ratio (Annual)4.18x

Asset Turnover (Annual)0.16x

52-Week High$2.62

Operating Margin (5Y Avg)-158.70%

EPS Excl Extra (Annual)$1.43

Tangible BV CAGR (5Y)-3.76%

26-Week Price Return-15.57%

Quick Ratio (Annual)1.36x

13-Week Price Return-14.55%

Total Debt / Equity (Annual)0.84x

Current Ratio (Quarterly)1.77x

Enterprise Value$144.98M

Revenue / Share Growth (5Y)-42.44%

Asset Turnover (TTM)0.17x

Book Value / Share Growth (5Y)2.39%

Revenue / Employee (Annual)$286,900

Inventory Turnover (Annual)0.38x

Pretax Margin (Annual)-434.23%

Cash / Share (Annual)$1.42

3-Month Return Std Dev68.94%

Gross Margin (5Y Avg)52.25%

Net Income / Employee (TTM)$-898,900

EBITDA CAGR (5Y)-13.04%

ROE (Last FY)275.39%

Net Interest Coverage (Annual)-18.03x

EPS Basic Excl Extra (Annual)$1.43

P/FCF (TTM)1.99x

Receivables Turnover (TTM)5.36x

Total Debt / Equity (Quarterly)0.85x

EPS Incl Extra (TTM)$-1.03

Receivables Turnover (Annual)0.65x

ROI (TTM)-107.16%

P/S Ratio (TTM)3.46x

Pretax Margin (5Y Avg)-166.75%

Revenue / Share (Annual)$0.36

Tangible BV / Share (Annual)$0.12

Price vs S&P 500 (52W)0.93%

P/E Ratio (TTM)1.05x

EPS Growth TTM (YoY)735.87%

Year-to-Date Return-0.70%

5-Day Price Return3.68%

EPS Normalized (Annual)$1.43

ROA (5Y Avg)-13.87%

Net Profit Margin (Annual)398.43%

Month-to-Date Return0.00%

Cash Flow / Share (TTM)$-2.49

EBITD / Share (Annual)$-1.51

Operating Margin (Annual)-429.51%

LT Debt / Equity (Annual)0.84x

ROI (5Y Avg)-6.87%

P/E Excl Extra (TTM)1.05x

LT Debt / Equity (Quarterly)0.85x

EPS Basic Excl Extra (TTM)$-1.03

P/TBV (Quarterly)13.63x

P/B Ratio (Annual)2.81x

Inventory Turnover (TTM)3.11x

Pretax Margin (TTM)-316.37%

Book Value / Share (Annual)$0.50

Price vs S&P 500 (13W)-16.50%

Net Margin Growth (5Y)70.34%

Beta0.97x

P/FCF (Annual)1.20x

Revenue / Share (TTM)$0.33

ROE (TTM)-183.36%

52-Week Low$1.09

vGradeB

gGradeC

mGradeC

vgmGradeC

CHRS Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	-$0.12	-$0.19	-65.22%(-$0.08)
Q1 2026	May 11, 2026	-$0.27	-$0.25	+5.66%(+$0.02)
Q4 2025	Mar 9, 2026	-$0.34	-$0.34	-1.49%(-$0.01)
Q3 2025	Nov 6, 2025	-$0.29	-$0.33	-13.79%(-$0.04)
Q2 2025	Aug 7, 2025	-$0.27	-$0.34	-25.19%(-$0.07)

CHRS Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.17

4.23

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
CHRSCoherus Oncology, Inc. Common Stock	B	C	C	$1.41
AMGNAmgen Inc	C	C	B	$432.42
GILDGilead Sciences Inc	C	B	B	$145.68
ARGXargenx SE American Depositary Shares	D	A	B	$1023.21
MRNAModerna, Inc. Common Stock	D	C	A	$137.99
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$207.88
BIIBBiogen Inc. Common Stock	C	D	B	$218.50
BNTXBioNTech SE American Depositary Share	C	C	C	$102.08
NBIXNeurocrine Biosciences Inc	C	B	C	$154.06
EXELExelixis Inc	C	B	B	$54.45
HALOHalozyme Therapeutics, Inc.	C	B	B	$105.35
TECHBio-Techne Corp.	D	C	B	$72.35
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$351.46
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.97
RGENRepligen Corp	D	C	B	$176.27
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$118.15
PCVXVaxcyte, Inc. Common Stock	—	—	B	$59.84
QGENQIAGEN N.V.	C	C	B	$43.11
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$141.38
IBRXImmunityBio, Inc. Common Stock	F	A	B	$8.05
IMVTImmunovant, Inc. Common Stock	—	—	B	$41.20
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$57.80
CGONCG Oncology, Inc. Common stock	F	A	B	$74.34
CRSPCRISPR Therapeutics AG	D	B	C	$57.72
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	$18.77
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$25.19
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.00
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.01
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.76
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$29.32
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.82
KODKodiak Sciences Inc Common Stock	—	—	B	$37.72
MESOMesoblast Limited American Depositary Shares	D	B	B	$17.44
VCELVericel Corporation	D	B	B	$40.95
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$44.84
ADMAADMA Biologics, Inc.	C	C	C	$9.34
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$36.62
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$5.77
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.83
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	$123.41
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.34
ALVOAlvotech Ordinary Shares	C	D	C	$4.95
NVAXNovavax Inc	B	D	C	$9.26
MAZEMaze Therapeutics, Inc. Common Stock	—	—	C	$27.44
SLBTSL Science Holding Limited Ordinary Shares	—	—	C	$2.70
REPLReplimune Group, Inc.	—	—	A	$15.50
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.45
VORVor Biopharma Inc. Common Stock	—	—	B	$22.65
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$21.70
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	B	$13.82
SANASana Biotechnology, Inc. Common Stock	—	—	B	$3.93

About Coherus Oncology, Inc. Common Stock

Coherus Oncology is a commercial-stage biotechnology company with LOQTORZI, an approved PD-1 inhibitor, and a pipeline of two mid-stage clinical candidates. The company is expanding LOQTORZI's use in nasopharyngeal cancer and exploring combination therapies with its pipeline candidates and industry partners. Key assets include LOQTORZI, CHS-114, and Casdozokitug, targeting liver, lung, head and neck, and other cancers.